Dynamic change of pd-l1 expression on circulating tumor cells in advanced solid tumor patients undergoing pd-1 blockade therapy
文献类型:期刊论文
作者 | Yue, Chunyan1,3; Jiang, Yubo2; Li, Ping1; Wang, Yuehua1; Xue, Jian4; Li, Nannan4; Li, Da4; Wang, Ruina6,7; Dang, Yongjun6,7; Hu, Zhiyuan1,3,5 |
刊名 | Oncoimmunology
![]() |
出版日期 | 2018 |
卷号 | 7期号:7页码:12 |
关键词 | Advanced solid tumor Circulating tumor cells (ctcs) Immunotherapy Programmed death-ligand 1 (pd-l1) Semi-quantitative analysis |
ISSN号 | 2162-402X |
DOI | 10.1080/2162402x.2018.1438111 |
通讯作者 | Hu, zhiyuan(huzy@nanoctr.cn) ; Yang, yanlian(yangyl@nanoctr.cn) ; Xu, jianming(jmxu2003@yahoo.com) |
英文摘要 | Background: tumor pd-l1 levels have predictive value in pd-1/pd-l1 checkpoint blockade therapies, yet biopsies can only provide baseline information. whether pd-l1 expression on circulating tumor cells (ctcs) could serve as an alternative biomarker is of great interest.design: we established an immunofluorescence assay for semi-quantitative assessment of the pd-l1 expression levels on ctcs with four categories (pd-l1(negative), pd-l1(low), pd-l1(medium) and pd-l1(high)). 35 patients with different advanced gastrointestinal tumors were enrolled in a phase 1 trial of a pd-1 inhibitor, ibi308. the ctc numeration and the pd-l1 expression levels were analyzed.results: prior the treatment of ibi308, 97% (34/35) patients had ctcs, ranging from1 to 70 (median 7). 74% (26/35) had pd-l1(positive) ctcs, and 60% (21/35) had at least one pd-l1(high) ctcs. the disease control (dc) rate in pd-l1(high) patients (48%) is much higher than the others (14%). the group with at least 20% abundance of pd-l1(high) ctcs had even higher dc rate of 64% (9/14), with only 14% dc rate for the rest (3/21). we also observed that the count changes of total ctc, pd-l1(postive) ctc and pd-l1(high) ctc correlate quite well with disease outcome (p<0.001, p = 0.002 and 0.007, respectively). in addition, the abundance of pd-l1(high) ctcs at baseline had predicative significance for progression free survival (pfs).conclusions: we revealed that the abundance of pd-l1(high) ctcs at baseline might serve as a predictor to screen patients for pd-1/pd-l1 blockade therapies and measuring the dynamic changes of ctc could indicate the therapeutic response at early time. |
WOS关键词 | CANCER-PATIENTS ; LUNG-CANCER ; MICROSATELLITE INSTABILITY ; CLINICAL-APPLICATIONS ; OPEN-LABEL ; IMMUNOTHERAPY ; NIVOLUMAB ; DNA ; ATEZOLIZUMAB ; METAANALYSIS |
WOS研究方向 | Oncology ; Immunology |
WOS类目 | Oncology ; Immunology |
语种 | 英语 |
WOS记录号 | WOS:000433549100002 |
出版者 | TAYLOR & FRANCIS INC |
URI标识 | http://www.irgrid.ac.cn/handle/1471x/2177489 |
专题 | 高能物理研究所 |
通讯作者 | Hu, Zhiyuan; Yang, Yanlian; Xu, Jianming |
作者单位 | 1.Natl Ctr Nanosci & Technol China, CAS Ctr Excellence Nanosci, CAS Key Lab Biomed Effects Nanomat & Nanosafety, CAS Key Lab Standardizat & Measurement Nanotechno, Beijing, Peoples R China 2.Acad Mil Med Sci, Affiliated Hosp Canc Ctr, 8 East St, Beijing 100071, Peoples R China 3.Univ Chinese Acad Sci, Sino Danish Coll, Beijing, Peoples R China 4.Nanopep Biotech Co, Beijing, Peoples R China 5.Fujian Med Univ, Sch Basic Med Sci, Ctr Neurosci Res, Fuzhou, Fujian, Peoples R China 6.Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Metab & Mol Med,Minist Educ, Shanghai, Peoples R China 7.Fudan Univ, Huashan Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China |
推荐引用方式 GB/T 7714 | Yue, Chunyan,Jiang, Yubo,Li, Ping,et al. Dynamic change of pd-l1 expression on circulating tumor cells in advanced solid tumor patients undergoing pd-1 blockade therapy[J]. Oncoimmunology,2018,7(7):12. |
APA | Yue, Chunyan.,Jiang, Yubo.,Li, Ping.,Wang, Yuehua.,Xue, Jian.,...&Xu, Jianming.(2018).Dynamic change of pd-l1 expression on circulating tumor cells in advanced solid tumor patients undergoing pd-1 blockade therapy.Oncoimmunology,7(7),12. |
MLA | Yue, Chunyan,et al."Dynamic change of pd-l1 expression on circulating tumor cells in advanced solid tumor patients undergoing pd-1 blockade therapy".Oncoimmunology 7.7(2018):12. |
入库方式: iSwitch采集
来源:高能物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。